Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J3397 Injection., vestronidase alfa-vjbk

J Codes (Drugs)

Also known as: vestronidase alfa, Mepsevii, lysosomal enzyme

Vestronidase alfa-vjbk (Mepsevii) injection is a recombinant lysosomal enzyme for sialidosis and galactosialidosis treatment.

In Plain Language

rare genetic disease treatment; enzyme replacement infusion

Clinical Context

Enzyme replacement therapy for sialidosis and galactosialidosis. Recombinant sialidase administered intravenously. Reduces accumulation of sialylated glycoproteins in lysosomal storage diseases.

RVU Information

CPT J3397 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

Rare Disease SpecialistsGenetic MedicinePediatrics

Frequently Asked Questions

What is CPT code J3397?

CPT J3397 (Injection., vestronidase alfa-vjbk) is a J Codes (Drugs) code. Vestronidase alfa-vjbk (Mepsevii) injection is a recombinant lysosomal enzyme for sialidosis and galactosialidosis treatment.

How is J3397 administered?

CPT J3397 is administered by a healthcare provider, typically via injection or infusion. Enzyme replacement therapy for sialidosis and galactosialidosis. Recombinant sialidase administered intravenously. Reduces accumulation of sialylated glycoproteins in lysosomal storage diseases. It is used by Rare Disease Specialists, Genetic Medicine, Pediatrics.

When is CPT J3397 used?

Enzyme replacement therapy for sialidosis and galactosialidosis. Recombinant sialidase administered intravenously. Reduces accumulation of sialylated glycoproteins in lysosomal storage diseases.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.